Business Context and Reporting Period
This Form 8-K was filed by Werewolf Therapeutics, Inc. (NASDAQ: HOWL) on October 2, 2025. The report addresses a material event occurring on September 30, 2025, involving the passing of Dr. Alon Lazarus, Ph.D., a member of the Company's Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and listing compliance matters.
Material Changes
- Board Composition: The death of Dr. Lazarus reduced the number of directors on the Audit Committee to two.
- Listing Compliance: The reduction in Audit Committee members rendered the Company noncompliant with Nasdaq Listing Rule 5605(c)(2), which mandates a minimum of three members.
- Regulatory Notification: The Company notified Nasdaq of this non-compliance on October 2, 2025.
Outlook, Risks, and Management Commentary
Management expressed condolences for Dr. Lazarus's passing and acknowledged his service since August 2019. The Company is currently in a cure period granted by Nasdaq to regain compliance, which expires on the earlier of the next annual meeting of stockholders or September 30, 2026. The Board plans to appoint an additional independent director to fill the vacancy on the Audit Committee at the earliest opportunity.
Investor Verification Checklist
- Confirm the timeline for the appointment of a new independent director to the Audit Committee.
- Monitor future filings for the specific date of the next annual meeting of stockholders to determine the exact expiration of the cure period.
- Verify that the new appointee meets Nasdaq independence and qualification criteria.